25 results
8-K
EX-2.1
IKNA
Ikena Oncology Inc
7 Aug 23
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
8:02am
promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.
(d) Except as set forth on Section 4.7(d) of the Parent Disclosure
8-K
EX-1.1
IKNA
Ikena Oncology Inc
15 May 23
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
9:09am
Oversight Board (“PCAOB”), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01
S-3
EX-1.2
mny2fywwrhub9kpb
27 Apr 22
Shelf registration
5:17pm
DEF 14A
2msjvtq66b9sfa
27 Apr 22
Definitive proxy
4:32pm
10-K
750jgn156q5wnxw
17 Mar 22
Annual report
6:31am
10-Q
8j435b zb9z
13 May 21
Quarterly report
4:15pm
424B4
o8yi1 cpfbv
26 Mar 21
Prospectus supplement with pricing info
5:04pm
S-1/A
ylxkf 4qzqsedm1
22 Mar 21
IPO registration (amended)
8:51am
S-1/A
EX-1.1
jaraen5asb6xfw
22 Mar 21
IPO registration (amended)
8:51am
S-1
ifmz44rv 886
5 Mar 21
IPO registration
2:59pm